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Sir, – A unique case of Potocki Schaffer 
syndrome (PSS) was reported previously [1], 
but at that time the diagnosis could not be ge-
netically confirmed. Here, we delineate more 
detailed neuropathological findings, present 
a detailed list of deleted genes confirmed by 
array comparative genomic hybridization 
(aCGH), and discuss possible genotype/phe-
notype relations in this patient.
In short, in addition to obligate exostoses 
(EXT) and parietal foramen (FPP), the pa-
tient also suffered from severe intellectual 
disability (ID). Motor development was also 
retarded with documented regression of mo-
tor function at the age of 3. After puberty, 
athetotic movements and seizures developed. 
In later life, he suffered from recurrent respi-
ratory tract infections, anemia, thrombocy-
topenia, and finally generalized edema. He 
never walked alone, he was non-verbal and 
unable to perform activities of daily living. 
He manifested craniofacial anomalies (CFA) 
including a high and broad forehead, brachy-
cephaly, a long narrow pointed nose, strabis-
mus, thin palpebral fissures, the absence of 
eyebrows, large dysplastic low set ears, and 
a hypoplastic mandible (Figure 1A). At vari-
ous hospital admissions, obesity, cryptorchi-
dism, over stretchable joints, contractures, 
osteoporosis, hip dysplasia, and hypertrophic 
cardiomyopathy were noted. Shortly before 
death, a cranial computerized tomography 
(CCT) scan at the age of 33 demonstrated, 
in addition to micrencephaly, severe brain 
atrophy with hydrocephalus e vacuo, a large 
cavum Vergae, and choroid plexus arachnoid 
cyst in the occipital horn of the left side ven-
tricle as well as hyperostosis frontalis (Fig-
ure 1B). These findings were also confirmed 
by autopsy on coronary slices of formalin-
fixed brain sections (Figure 1C).
Detailed histomorphological study of 
FPP revealed associated lipomatous tissue 
in the center (Figure 1D). Bony rims of FPP 
demonstrated dense predominantly lamellar 
bone. Despite rather large defects histomor-
phologically, FPP demonstrated remarkable 
preservation of bony lamellae, represent-
ing extreme thinning rather than true loss of 
bone (not shown). The hyperostosis frontalis 
spared the area of the sagittal sinus (Figure 
1E). Histomorphologically, the bone tissue 
was predominantly composed of lamellar 
bone, and the bone marrow contained fat 
tissue and hematopoietic cells (Figure 1F), 
and osteoclasts were infrequent and only 
observed with CD68 immunohistochemistry 
(Figure 1F inset). In the occipital horn of the 
left ventricle, an arachnoid cyst of the cho-
roid plexus was found (Figure 1G). Histol-
ogy revealed large cysts lined by arachnoid 
cells  (Figure  1H).  The  surrounding  tissue 
contained macrophages and psammoma bod-
ies. At the surface, little pre-existing choroid 
plexus was preserved. In the right ventricle, 
a choroid plexus cholesteatoma was found 
in the occipital horn (Figure 1I). Histology 
showed a typical cholesteatoma with numer-
ous cholesterol crystal clefts, macrophages, 
multinuclear giant cells of foreign body 
type, and siderophages in the fibrous stroma 
as well as some psammoma bodies (Figure 
1J). At autopsy, the detailed neuropatholog-
Clinical Neuropathology, Vol. 33 – No. 3/2014 – Letters to the editor  238Figure 1.  PSS phenotype, CCT, macroscopic findings, and histopathology. The patient at age 33 years (A); 
a CCT obtained shortly before death shows micrencephaly, severe brain atrophy with hydrocephalus evacuo, 
large cavum Vergae, and choroid plexus arachnoid cyst (B); coronal slice of formalin fixed brain at autopsy 
with large cavum Vergae and evacuo hydrocephalus (C); view of FPP from the internal aspect showing 
yellow fat tissue at the center (D), inset shows histology of the yellowish material disclosing lipomatous tis-
sue, hematoxylin-eosin stain, scale bar 200 µm; formalin fixed frontal bone with severe hyperostosis (E); 
transection of frontal bone (F), the outside is left, the epidural space at the right, bone marrow contains fat 
tissue and hematopoiesis, hematoxylin-eosin stain in polarized light, scale bar 2 mm, inset shows immuno-
histochemistry for CD68 indicating few small osteoclasts, alkaline phosphatase, scale bar 20 µm; arachnoid 
cyst of the choroid plexus of the left occipital horn (G); histology reveals large cysts lined by arachnoid cells, 
the surrounding contains macrophages and psammoma bodies, at the outer rims little pre-existing choroid 
plexus is delineated, hematoxylin-eosin stain, scale bar 1 mm (H); in the right occipital horn, the choroid 
plexus contained a cholesteatoma (I), typical histomorphological appearance of cholesteatoma with numer-
ous cholesterol crystal clefts, macrophages, multinuclear giant cells of foreign body type, siderophages, in 
the background fibrous stroma, and some psammoma bodies, hematoxylin-eosin stain, scale bar 500 µm (J).
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2013).
Gene/OMIM Name Phenotype or function: questionable (?), hypothetical (°) or 
likely (*) role in PSS
LRRC4C/608817 Leucine-rich repeat-containing protein 4C  Promotes outgrowth of thalamocortical axons?
API5/609774 Apoptosis inhibitor 5 Expression prevents apoptosis? 
TTC17 Tetratricopeptide repeat domain 17 Unknown?
HSD17B12/609574 17-beta-hydroxysteroid dehydrogenase XII Fatty acid elongation?
ALKBH3/610603 AlkB, E. coli, homolog of,3 Repair of single-stranded DNA lesions?  
ACCS/608405 1-aminocyclopropane-1-carboxylate synthase Catalyzes the deamination of L-vinylglycine?
EXT2/608210 Exostosin 2 Loss of activity causes hereditary multiple osteochon-
droma (exostoses)*p
ALX4/605420 Aristaless-like 4, mouse, homolog of Deletion or mutation results in foramina parietalia 
permagna*p, polydactyly°
CD82/600623 CD 82 antigen, formerly: KAI1 Metastasis suppressor gene, activation of T-cells?  
TSPAN18 Tetraspanin 18 isoform 1 Unknown?
TP53I11 Tumor protein p53-induced protein Unknown?
PRDM11 PR domain containing 11 Unknown?
SYT13/607716 Synaptotagmin 13 Vesicular traffic, exocytosis, and secretion, neurotransmitter 
release? 
CHST1/603797 Carbohydrate sulfotransferase1 Corneal transparency, macular corneal dystrophy? 
SLC35C1/605881 Solute carrier family 35, member C1, formerly: 
FUCT1
Congenital disorder of glycosylation type IIc with 
immunodeficiency°p and severe mental and growth 
retardation°p, brain malformations°p, seizures°p,  
hypotonia°p, recurrent infections°p, bleeding disorder°p
CRY2/603732 Cryptochrome 2  Regulator of circadian feedback loop?  
MAPK8IP1/604641 Mitogen-activated protein kinase 8-interacting 
protein 1
Non-insulin-dependent diabetes mellitus°p, adipositas°p, 
CNS damage°p, genitourinary abnormalities°p  
PEX16/603360 Peroxisome Biogenesis Factor 16 Zellweger syndrome, peroxisomal disorder – candidate? for 
craniofacial anomalies°p, mental and growth retardation°p, 
hypotonia°p, seizures°p 
GYLTL1B/609709 Glycosyltransferase-like 1B Unknown?
PHF21A/608325 PHD finger protein 21A Repression of neuron-specific genes - causative for 
intellectual disability and craniofacial anomalies*p [9]
CREB3L1 CAMP responsive element binding protein 
3-like 1
Transcription factor; acts during endoplasmic reticulum 
stress by activating unfolded protein response target genes?
DGKZ/601441 Diacylglycerol kinase, zeta T-cell regulation? 
MDK/162096 Midkine, formerly NEGF2 Angiogenesis, cell growth, and cell migration – candidate for 
brain malformation°p, mental retardation°p, seizures°p
CHRM4/118495 Cholinergic receptor, muscarinic, 4  Unknown?
AMBRA1/611359 Activating molecule in beclin 1-regulated 
autophagy
Neural development – candidate for brain malformation with 
nodular heterotopias°p
HARBI1/615086 Harbinger transposase derived 1 Transposase-derived protein that may have nuclease activity 
(potential). Does not have transposase activity?
ATG13/615088 Autophagy-related protein 13 Unknown?
ARHGAP1/602732 Rho GTPase-activating protein 1 Cell migration – candidate for brain malformation with 
nodular heterotopias°p
ZNF408 Zinc finger protein 408 May be involved in transcriptional regulation?
F2/176930 Coagulation factor II Hypo-, dys-, or hyper-prothrombinemia, thromboses, 
hemorrhages; bleeding disorder°p
CKAP5/611142 Cytoskeleton-associated protein 5 Microtubule organization?
LRP4/604270 Low density lipoprotein receptor-related 
protein 4
Sclerosteosis 2, brachydactyly or syndactyly. Associated 
with Cenani-Lenz syndactyly syndrome and Mulefoot 
disease?
C11orf49 Chromosome 11 open reading frame 49 Interacts with uranyl acetate?
ARFGAP2/606908 ADP-ribosylation factor GTPase-activating 
protein 2
Unknown?
PACSIN3/606513 Protein kinase C and casein kinase substrate 
in neurons 3
Vesicle formation and transport?
DDB2/600811 DNA damage-binding protein 2 Repair of DNA damage induced by UV radiation; xeroderma 
pigmentosum groupe E?
Clinical Neuropathology, Vol. 33 – No. 3/2014 – Letters to the editor  240ic examination of the micrencephalic brain 
revealed evidence of two separate diseases. 
First, a disturbance of mass growth of neu-
rons with micrencephaly, periventricular 
nodular heterotopias, a small degree of corti-
cal dysplasia of the cerebellum, sometimes 
grouped nodular heterotopias, and, not men-
tioned in the previous report, single ectopic 
ganglion cells were scattered in the subcorti-
cal white matter of the cerebral hemispheres. 
The second central nervous system (CNS) 
disease included symmetric accumulations 
of macrophages at certain sites in the white 
matter  and  cortex  as  described  earlier  [1]. 
Gene/OMIM Name Phenotype or function: questionable (?), hypothetical (°) or 
likely (*) role in PSS
ACP2/171650 Acid phosphatase 2, lysosomal Lysosomal storage°, mental and growth retardation °p, 
seizures°p, hypotonia°p, osteoporosis°p, hyperostosis 
frontalis°p, craniofacial dysostosis°p, bleeding disorder°p, 
edemas°p
NR1H3/602423 Nuclear receptor subfamily 1, group H, 
member 3
Lipid homeostasis, cholesterol accumulation in peripheral 
tissues, adipositas°p, cardiovascular disease, reduced 
inflammation or macrophage function.
MADD/603584 MAP kinase-activating death domain Prevents apoptotic signaling  – candidate for brain malfor-
mation with nodular heterotopias°p
MYBPC3/600958 Myosin-bindig protein C, cardiac  Cardiomyopathy*p
SPI1/165170 Spleen focus forming virus  proviral integra-
tion oncogene SPI1, aka PU.1
Transcription factor of hematopoietic cells, arrested bone 
resorption and osteopetrosis, hyperostosis frontalis°p
SLC39A13/608735 Solute carrier family 39 (zinc transporter), 
member 13
Skeletal and dental abnormalities. Ehlers-Danlos syndrome-
like spondylocheirodysplasia?
PSMC3/186852 Proteasome 26S subunit, ATPase, 3 Tat-mediated transcriptional activation?
RAPSN/601592 Receptor-associated protein of the synapse, 
43-KD
Myasthenia, fetal akinesia syndrome?
CUGBP1/601074 CUG triplet repeat, RNA-binding protein 1 RNA-binding protein implicated in the regulation of several 
post-transcriptional events; pre-mRNA alternative splicing; 
mRNA translation and stability?
PTPMT1/609538   Protein-tyrosine phosphatase, mitochondrial, 
1
Protein phosphatase; specifically mediates dephosphoryla-
tion of mitochondrial proteins, thereby playing an essential 
role in ATP production?
KBTBD4 Kelch repeat and BTB (POZ) domain 
containing 4
Interacts with acetaminophen?
NDUFS3/603846 NADH-ubiquinone oxido-reductase Fe-S 
protein 3
Complex I, mitochondrial respiratory chain defect; Leigh 
syndrome?
FAM180B Family with sequence similarity 180, member 
B
Unknown?
C1QTNF4/614911 Complement C1q and tumor necrosis factor 
related protein 4
Unknown?
MTCH2/613221 Mitochondrial carrier homolog 2 Mitochondrial protein?
AGBL2 ATP/GTP binding protein-like 2 Cytoplasmic metallocarboxypeptidase; may play a role in 
regulation of microtubuli organization?
FNBP4/615265 Formin binding protein 4 Binds FMN1. Interacts with the Arg/Gly-rich-flanked Pro-rich 
of KHDRBS1/SAM68? 
NUP160/607614 Nucleoporin, 160-KD Mediation of RNA export from the nucleus?








Olfactory receptor, family 4 Interact with odorant molecules in the nose, to initiate a 
neuronal response that triggers the perception of a smell?
FOLH1/600934 Folate hydrolase 1 Impaired intestinal absorption of dietary folates with 
consequent hyperhomocysteinemia with increased risk for 
cardiovascular disease – adipositas°p, neural tube defects, 
and cognitive deficits°p; glutamate excitotoxicity. 
Top to bottom equals telomere to centromere direction; psymptoms and signs present in the patient described here.
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age disease and fit well with the clinically 
described decline of motor function.
For the array CGH, DNA was extracted 
from formalin fixed and paraffin embedded 
brain tissue of the patient. In short, an Agi-
lent 244K human genome oligonucleotide 
CGH microarray (G4411B) was used for ar-
ray CGH analysis following the manufactur-
er’s instructions. Images were captured by an 
Agilent scanner at the resolution of 2 µm and 
quantified using Feature Extraction software 
v9.0 (Agilent Technologies, Palo Alto, CA, 
USA). CGH analytics software v3.4 (Agilent 
Technologies, Palo Alto, CA, USA) was sub-
sequently used for data normalization, qual-
ity evaluation, and data visualization. Copy 
number variants (CNV) were called using 
the ADM-2  (Aberration  Detection  Method 
2) algorithm. A minimum of five probes was 
required to meet the size cut-off for a CNV. 
The average inter-probe spacing is ~ 8.9 Kb, 
thus the average CNV detection sensitivity 
is ~ 45 Kb.
This study revealed an 11.9 Mb deletion 
at 11p between 38,824,655 and 50,638,770 
(hg18).  The  karyotype  was  confirmed  as 
del(11)(p11.12p12).  An  OMIM  database 
search  revealed  more  than  50  annotated 
genes in this region (Table 1).
Included are ALX4, which explains FPP, 
EXT2 accounting for multiple exostoses, and 
the MYBPC3 gene involved in hypertrophic 
cardiomyopathy (HCM) of the patient. Thus, 
not only the PSS was confirmed, but also that 
the patient is the first to be described with 
documented hypertrophic cardiomyopathy 
(HCM). Diagnosis of HCM during his life-
time was probably possible because he is the 
oldest one so far reported with PSS permit-
ting development of a cardiomyopathy. Fur-
thermore, all genes postulated to be deleted 
in the first report were validated in addition 
to others [1].
Besides FPP and EXT, for which the 
genes ALX4 and EXT2 are well established, 
osteoporosis and hyperostosis frontalis were 
additional features observed in this patient. 
The simultaneous occurrence of bone loss, 
such as osteoporosis and FPP, and gain of 
bone material at other sites, i.e., EXT and 
hyperostosis  frontalis,  is  quite  remarkable. 
A possible explanation could be related to 
selective  vulnerability/susceptibility  of  dif-
ferent bones at different sites and different 
gene  expression  status.  Different  types  of 
ossification or osteogenesis of bones, i.e., in-
tramembranous vs. enchondral ossification, 
might explain these differences. The parietal 
bones ossify intramembranously from os-
sification centers that appear during the 8th 
and 9th weeks of fetal life. From the litera-
ture, it is known that there is a size reduction 
of FPP with advancing age (mechanical or 
disclosure type defect), but there can also be 
a more prominent intracranial phenotype in 
consecutive generations [2].
Indeed, the patient described here is the 
first one with PSS with detailed pathologic 
macroscopic and microscopic findings. The 
more detailed histomorphological findings of 
FPP described here reveal that the true bony 
defect resulted from extreme thinning of the 
parietal bone. Because there are no vessels 
or any other structures entering or exiting the 
cranial vault at this site, the terms “hereditary 
bi-parietal diminished/delayed ossification”, 
“parietal bone hypoplasia”, or “thinning of 
the parietal bone” might actually better char-
acterize the underlying pathology. The origin 
of the lipomatous tissue at this site remains 
obscure, but a malformative genesis appears 
most likely. As described in our previous re-
port, osteoporosis might be associated with 
ACP2 [1].
A candidate gene for hyperostosis fron-
talis would be SPI1 as failure to express the 
gene product might preclude development 
of osteoclasts, leading to arrested bone re-
sorption and osteopetrosis [3]. Indeed, our 
detailed histomorphological search of os-
teoclasts in the area of hyperostosis frontalis 
revealed relatively few small osteoclasts that 
were only detectable by means of immu-
nohistochemistry.  Hyperplasia  of  calvarial 
bones was also described as a CCT finding 
by Wuyts et al. [4].
The candidate region for intellectual 
disability (ID) in PSS was previously lo-
calized to 11p11.2 between D11S1361 and 
D11S1344, which is the same region postu-
lated for craniofacial abnormalities (CFA) 
[5, 6]. PHF21A was identified after the can-
didate gene region was narrowed to 1.1 Mb 
by deletion mapping and after PHF21A was 
found to be disrupted in 3 unrelated balanced 
translocation patients with ID and craniofa-
cial  anomalies  [7].  Furthermore,  the  work 
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additional locus in the region telomeric to 
EXT2 [4]. Apart from PHF21A responsible 
for ID and CFA [7], several other candidate 
genes for both phenotypes include PEX16 
and ACP2, whereas ID alone could be re-
lated to SLC35C1, MDK, AMBRA1, ARH-
GAP1, MADD, or FOLH1. Multiple loci for 
ID are further supported by the phenotype. 
Two different diseases, a CNS malformation 
and a metabolic disease, imply two different 
genes for ID.
The brain malformations including mi-
crencephaly,  ventriculomegaly  i.e.,  hydro-
cephalus e vacuo, cavum Vergae, nodular 
heterotopias, and cerebellar cortical dyspla-
sia, which is now supplemented by scattered 
ectopic ganglion cells, are obviously due to 
disturbed growth of neurons. In the previous 
report [1], two candidate genes were identi-
fied: SLC35C1 and MDK. As delineated in 
Table 1, there are now some additional can-
didate genes expressed in the brain that are 
involved in apoptosis, migration, or neural 
development. These additional genes include 
API5, AMBRA1, ARHGAP1, and MADD.
To date, no other PSS patient with an ad-
ditional metabolic storage disease has been 
described. Also,  regression  of  motor func-
tion was not clinically documented in other 
reported PSS patients. Thus, this phenotype 
might constitute a new and separate syn-
drome.  The  candidate  gene  for  metabolic 
disease is ACP2, which constitutes a sepa-
rate ID locus because it is located in a cen-
tromeric direction from the generally pos-
tulated ID locus in PSS between D11S1361 
and D11S1344.
For  the  first  time,  the  detailed  macro-
scopic and microscopic findings of a choroid 
plexus cholesteatoma and choroid plexus 
arachnoid cyst of a PSS patient are report-
ed. The cholesteatoma might be a sequelae 
due to high amounts of fatty acids. Genes 
with influence on fatty acid metabolism in-
clude HSD17B12, MAPK8IP1, NR1H3 and 
FOLH1, all of which might also be respon-
sible for obesity and consequent morbidities. 
A choroid plexus cyst seems to be a recurrent 
finding of PSS as it has been described in 1 
patient (PSS12) in the series of Wakui et al. 
[5] and in a recent series in 2 of 6 patients 
studied with magnetic resonance imaging 
(MRI) [8].
Despite several imaging studies, patients 
with nodular heterotopias have not been re-
ported previously [4, 5, 8, 9, 10, 11, 12]. CT 
might not provide sufficient resolution, but 
MRI might be able to delineate these lesions.
In conclusion, the previously described 
unique clinical description of a patient with 
PSS  was  confirmed  by  array  CGH.  This 
male is the oldest PSS patient described so 
far, the only singular individual with hyper-
trophic cardiomyopathy linked to deletion 
of   MYBPC3,  and  the  first  autopsied  with 
detailed neuropathologic studies. The unam-
biguous presence of two different CNS dis-
eases suggests that there are at least two loci 
or  genes  for  intellectual  disability  in  PSS. 
This assumption is also supported by the 
clinical course of the patient with early intel-
lectual disability and later regression and de-
velopment of athetotic movements and sei-
zures. Arachnoid cysts of the choroid plexus 
are recurrent findings of PSS. Detailed his-
tomorphological studies of the FPP revealed 
extreme thinning and hypoplasia of the pa-
rietal bone resembling hereditary bi-parietal 
diminished/delayed  ossification  rather  than 
true foramina of the parietal bone.
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